Silver Nanoparticles in Biomedical Applications

Nanotoxicology: Progress toward Nanomedicine

Volumn , Issue , 2014, Pages 405-421

  Samberg, Meghan E ^a   Monteiro Riviere, Nancy A ^b  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896543524     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16562-30     Document Type: Chapter

References (71)

1. Auffan M, Rose J, Bottero J-Y, Lowry GV, Jolivet J-P, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 2009;4:634-41.
2. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanoscale. Science 2006;311:622-27.
3. Korkin A, Gusev E, Labanowski JK, Luryi S, eds. Nanotechnology for Electronic Materials and Devices. New York, NY: Springer, 2007:1-368.
4. Nalwa HS. Nanomaterials for Energy Storage Applications. Valencia, CA: American Scientific Publishers, 2009:350.
5. Gouma P. Nanomaterials for Chemical Sensors and Biotechnology. Singapore: Pan Stanford Publishing, 2010:1-159.
6. Lucintel (Global Market Research Firm). Growth Opportunities in Global Nanomaterials Market 2011-2016. Trend, Forecast, and Opportunity Analysis. Dallas, TX: Research and Markets, 2011:1-153.
7. Woodrow Wilson Center (WWC). Project on Emerging Nanotechnologies. http://www. nanotechproject.org/inventories/consumer/analysis_draft/. Accessed April 29, 2013
8. The Project for Emerging Nanotechnology. Updated March 2011. www.nanotechproject. org Accessed April 4, 2013.
9. Coello R, Charlett A, Ward V, Wilson J, Pearson A, Sedgwick J, Borriello P. Device-related sources of bacteraemia in English hospitals-opportunities for the prevention of hospital-acquired bacteraemia. J Hosp Infect 2003;53(1):46-57.
10. Harmata M. Silver in organic chemistry. Hoboken, NJ: John Wiley and Sons. 2010:1-402.
11. Nordberg GF, Gerhardsson LS. In Seiler HG, Sigel H, eds. Handbook on Toxicity of Inorganic Compounds, New York, NY: Marcel Dekker, 1988:619-24.
12. Lehmann J, Merschdorf M, Pfeiffer W, Thon A, Voll S, Gerber G. Surface plasmon dynamics in silver nanoparticles studied by femtosecond time-resolved photoemission. Phys Rev Lett 2000;85(14):2921-24.
13. Haes AJ, Van Duyne RP. A nanoscale optical biosensor: Sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles. J Am Chem Soc 2002;124(35):10596-604.
14. Bosbach J, Hendrich C, Stietz F, Vartanyan T, Träger F. Ultrafast dephasing of surface plasmon excitation in silver nanoparticles: Influence of particle size, shape, and chemical surrounding. Phys Rev Lett 2002;89(25):257404.
15. Liao H, Hehl CL, Hafner JH. Biomedical applications of plasmon resonant metal nanoparticles. Nanomedicine 2006;1(2):201-8.
16. Yguerabide J, Yguerabide EE. Light-scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications. II. Experimental characterization. Anal Biochem 1998;262:157-76.
17. Schultz S, Smith DR, Mock JJ, Schultz DA. Single-target molecule detection with nonbleaching multicolor optical immunolabels. Proc Natl Acad Sci USA 2000;97:996-1001.
18. Schultz DA. Plasmon resonant particles for biological detection. Curr Opin Biotechnol 2003;14:13-22.
19. Angelotti N, Martini P. Treatment of skin ulcers and wounds through the centuries. Minerva Med 1997;88(1-2):49-55.
20. Crede CSF. Die verhutung der augenentzundung der neugeborenen [The prevention of eye inflammation of the newborn]. Arch Gynakol 1881;17:50-53.
21. Chen X, Schluesener HJ. Nanosilver: A nanoproduct in medical application. Toxicol Lett 2008;176:1-12.
22. Sun Y, Xia Y. Shape-controlled synthesis of gold and silver nanoparticles. Science 2002;298(5601):2176-79.
23. Prabakar K, Sivalingam P, Mohamed Rabeek SI, Muthuselvam M, Devarajan N, Arjunan A, Karthick R, Suresh MM, Wembonyama JP. Evaluation of antibacterial efficacy of phyto fabricated silver nanoparticles using Mukia scabrella (Musumusukkai) against drug resistance nosocomial gram negative bacterial pathogens. Colloids Surf B Biointerfaces 2013;104:282-288.
24. Raveendran P, Fu J, Wallen SL. Completely “green” synthesis and stabilization of metal nanoparticles. J Am Chem Soc 2003;125(46):13940-41.
25. Oluwafemi OS, Lucwaba Y, Gura A, Masabeya M, Ncapayi V, Olujimi OO, Songca SP. A facile completely ‘green’ size tunable synthesis of maltose-reduced silver nanoparticles without the use of any accelerator. Colloids Surf B Biointerfaces 2013;102:718-23.
26. Nakamura M. Approaches to the biofunctionalization of spherical silica nanomaterials. In Kumar CSSR, ed. Nanotechnologies for the life sciences. Verlag, Germany: Wiley-VCH, 2010.
27. Masala O, Seshadri R. Synthesis routes for large volumes of nanoparticles. Annu Rev Mater Res 2004;34:41-81.
28. Su HL, Chou CC, Hung DJ, Lin SH, Pao IC, Lin JH, Huang FL, Dong RX, Lin JJ. The disruption of bacterial membrane integrity through ROS generation induced by nanohybrids of silver and clay. Biomaterials 2009;30(30):5979-87.
29. Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, Tam PK, Chiu JF, Chen CM. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J Proteome Res 2006;5:916-24.
30. Dror-Ehre A, Mamane H, Belenkova T, Markovich G, Adin A. Silver nanoparticle-E. coli colloidal interaction in water and effect on E. coli survival. J Colloid Interface Sci 2009;339:521-6.
31. Samberg ME, Orndorff PE, Monteiro-Riviere NA. Antibacterial efficacy of silver nanoparticles of different sizes, surface conditions and synthesis methods. Nanotoxicology 2011;5(2):244-53.
32. Wijnhoven SWP, Peijnenburg WJGM, Herberts CA, Hagens WI, Oomen AG, Heugens EHW, Roszek B et al. Nano-silver: A review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 2009;3(2):109-38.
33. Harvey MA. Critical-care-unit bedside design and furnishings: Impact on nosocomial infections. Infect Control Hosp Epidemiol 1998;19:597-601.
34. Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995;16:577-81.
35. Boyce JM, Potter-Bynoe G, Chenevert C, King T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: Possible infection control implications. Infect Control Hosp Epidemiol 1997;18:622-7.
36. Sexton T, Clarke P, O’Neill E, Dilland T, Humphreys H. Environmental reservoirs of methicillin-resistant Staphylococcus aureus in isolation rooms: Correlation with patient isolates and implications for hospital hygiene. J Hosp Infect 2006;62:187-94.
37. Klevens RM, Edwards JR, Richards Jr. CL, Horan TC, Gaynes RP, Pollock DA, Cardo MD. Estimating health care-associated infections and deaths in U.S. hospitals. CDC Public Health Rep 2002;122:160-6.
38. Eby DM, Luckarift HR, Johnson GR. Hybrid antimicrobial enzyme and silver nanoparticle coatings for medical instruments. ACS Appl Mater Interfaces 2009;1(7):1553-60.
39. Zhang D, Chen L, Zang C, Chen Y, Lin H. Antibacterial cotton fabric grafted with silver nanoparticles and its excellent laundering durability. Carbohydr Polym 2013;15;92(2):2088-94.
40. Mermel LA. New technologies to prevent intravascular catheter-related bloodstream infections. Emerg Infect Dis 2001;7(2):197-9.
41. Martínez-Gutiérrez F, Guajardo-Pacheco JM, Noriega-Trevino ME, Thi EP, Reiner N, Orrantia E, Av-Gay Y, Ruiz F, Bach H. Antimicrobial activity, cytotoxicity and inflammatory response of novel plastics embedded with silver nanoparticles. Future Microbiol 2013;8(3):403-11.
42. Stevens KN, Crespo-Biel O, van den Bosch EE, Dias AA, Knetsch ML, Aldenhoff YB, van der Veen FH, Maessen JG, Stobberingh EE, Koole LH. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials 2009;30(22):3682-90.
43. Roe D, Karandikar B, Bonn-Savage N, Gibbins B, Roullet JB. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J Antimicrob Chemother 2008;61(4):869-76.
44. Chou CW, Hsu SH, Wang PH. Biostability and biocompatibility of poly(ether)urethane containing gold or silver nanoparticles in a porcine model. J Biomed Mater Res A 2008;84(3):785-94.
45. ®) vs conventional catheters in intensive care unit patients. J Hosp Infect 2012;82:101-7.
46. Böswald M, Lugauer S, Regenfus A, Braun GG, Martus P, Geis C, Scharf J, Bechert T, Greil J, Guggenbichler JP. Reduced rates of catheter-associated infection by use of a new silver-impregnated central venous catheter. Infection 1999;27(Suppl 1):S56-S60.
47. Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Craven DE et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: The NASCENT randomized trial. JAMA 2008;300(7):805-13.
48. Balasz DJ, Koerner E, Hossain MM, Hegemann D. Multi-functional nanocomposite plasma coatings-enabling new applications in biotechnology. Proceedings of NanoEurope, St. Gallen Switzerland, 2006.
49. Wagener M. Silver based nanocomposites for antimicrobial medical devices. Proceedings of NanoEurope, St. Gallen, Switzerland, 2006.
50. Moyer CA, Brentano L, Gravens DL, Margraf HW, Monafo WW Jr. Treatment of large human burns with 0.5% silver nitrate solution. Arch Surg 1965;90:812-67.
51. Miller CN, Newall N, Kapp SE, Lewin G, Karimi L, Carville K, Gliddon T, Santamaria NM. A randomized-controlled trial comparing cadexomer iodine and nanocrystalline silver on the healing of leg ulcers. Wound Repair Regen 2010;18(4):359-67.
52. Friedman AJ, Phan J, Schairer DO, Champer J, Qin M, Pirouz A, Blecher-Paz1 K et al. Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: A targeted therapy for cutaneous pathogens. J Invest. Dermatol 2013;133:1231-9.
53. Langer R. Tissue engineering: Perspectives, challenges, and future directions. Tissue Eng 2007;13(1):1-2.
54. Tateishi T, Chen G, Ushida T. Biodegradable porous scaffolds for tissue engineering. J Artif Organs 2002;5:77-83.
55. Chung S, Ingle NP, Montero GA, Kim SH, King MW. Bioresorbable elastomeric vascular tissue engineering scaffolds via melt spinning and electrospinning. Acta Biomaterialia 2010; 6(6):1958-67.
56. Jeong SI, Kim SH, Kim YH, Jung Y, Kwon JH, Kim BS, Lee YM. Manufacture of elastic biodegradable PLCL scaffolds for mechano-active vascular tissue-engineering. J Biomater Sci Polym Ed 2004;15:645-60.
57. Jeong SI, Kwon JH, Lim JI, Cho SW, Jung Y, Sung WJ, Kim SH et al. Mechano-active tissue engineering of vascular smooth muscle using pulsatile perfusion bioreactors and elastic PLCL scaffolds. Biomaterials 2005;26:1405-11.
58. Kim B-S, Nikolovski J, Bonadio J, Mooney DJ. Cyclic mechanical strain regulates the development of engineered smooth muscle tissue. Nat Biotechnol 1999;17:979-83.
59. Kim B-S, Mooney DJ. Scaffold for engineering smooth muscle under cyclic mechanical strain conditions. J Biomech Eng 2000;122:210-15.
60. Jeon HJ, Kim JS, Kim TG, Kim JH, Yu W-R, Youk JH. Poly(ε-caprolactone)-based polyurethane nanofibers containing silver nanoparticles. Appl Surf Sci 2008;254:5886-90.
61. 2 for efficient lithium-ion intercalation. J Phys Chem C 2008;112(30):11175-80.
62. Samberg ME, Mente P, He T, King MW, Monteiro-Riviere NA. Incorporation of silver nanoparticles into a degradable poly(l-lactide-co-epsilon-caprolactone) copolymer scaffold for skin regeneration. Toxicologist 2013;132(1326):284.
63. Samberg ME, Oldenburg SJ, Monteiro-Riviere NA. Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro. Environ Health Perspect 2010;118(3):407-13.
64. Christensen FM, Johnston HJ, Stone V, Aitken RJ, Hankin S, Peters S, Aschberger K. Nano-silver-feasibility and challenges for human health risk assessment based on open literature. Nanotoxicology 2010;4:1-12.
65. Poon VK, Burd A. In vitro cytotoxicity of silver: Implication for clinical wound care. Burns 2004;30(2):285-6.
66. Cochrane C, Walker M, Bowler P, Parsons D, Knottenbelt D. The effect of several silver-containing wound dressings on fibroblast function in vitro using the collagen lattice contraction model. Wounds 2006;18(2):29-34.
67. Temple RM, Farooqi AA. An elderly, slate-grey woman. Practitioner 1985;229:1053-54.
68. Innes ME, Umraw N, Fish JS, Gomez M, Cartotto RC. The use of silver coated dressings on donor site wounds: A prospective, controlled matched pair study. Burns 2001;27(6):621-27.
69. Huang D-M, Chung T-H, Hung Y, Lu F, Wu SH, Mou CY, Yao M, Chen YC. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells. Tox Appl Pharma 2008;231:208-15.
70. Moiemen NS, Shale E, Drysdale KJ, Smith G, Wilson YT, Rapini R. Acticoat dressing and major burns: Systemic silver absorption. Burns 2011;37:27-35.
71. Gupta A, Silver S. Silver as a biocide: Will resistance become a problem? Nat Biotechnol 1998;16:888.